◀ Back to MAPK13
MAPK13 — SST
Text-mined interactions from Literome
Cattaneo et al., FEBS Lett 2000
(MAP Kinase Signaling System...) :
In previous studies we have showed that
somatostatin (SST) inhibits cell division,
mitogen activated protein ( MAP ) kinase and Ras activity in the human neuroblastoma cell line SY5Y
Ballarè et al., J Clin Endocrinol Metab 2001
(Acromegaly...) :
Moreover,
somatostatin reduced cell growth and
MAPK activity in WT but not in mutant cells in which the peptide even increased MAPK activity
Florio et al., Endocrinology 2003
(Neoplasms...) :
BN81658 reversed
somatostatin inhibition of cell proliferation, NO production, and
MAPK activity, indicating that SSTR3 activation is required for the effects of somatostatin in vitro
Wang et al., Am J Physiol Cell Physiol 2011
:
Furthermore, the somatostatin receptor SSTR2 antagonist CYN154806 could abolish
somatostatin induced NHE8 expression and p38
MAPK phosphorylation
Duran-Prado et al., Circ Res 2013
(Atherosclerosis...) :
Cortistatin inhibited platelet derived growth factor stimulated proliferation of human aortic SMCs via binding to
somatostatin receptors ( sst2 and sst5 ) and ghrelin receptor,
induction of cAMP and
p38-mitogen activated protein kinase , and inhibition of Akt activity
Shimizu et al., J Lipid Mediat Cell Signal 1996
:
Platelet activating factor and
somatostatin activate
mitogen activated protein kinase ( MAP kinase ) and arachidonate release
Florio et al., Mol Endocrinol 1999
:
Somatostatin activation of
mitogen activated protein kinase via somatostatin receptor 1 (SSTR1)